Introduction {#sec1-1}
============

The treatment of coronary artery disease was revolutionized by balloon angioplasty and stent implantation. However, common complications observed after coronary stent implantation are stent thrombosis, myocardial infarction (MI), and repeated need for revascularization (1). Stent thrombosis is particularly associated with a substantially increased (up to 30%) risk of death (2). Among other factors, a strong independent risk factor for major adverse cardiac events (MACE) is stent length. Stent length is associated with stent thrombosis, death, MI, and target lesion revascularization (TLR) (3-5). Besides acute adverse events, re-stenosis due to neointimal growth is still a major concern after stent implantation (6). After 5 years, 10% of drug-eluting stent-treated patients and 20%-30% of bare-metal stent treated patients experience in-stent restenosis (ISR) with need for repeat revascularization (7, 8). Drug-coated balloon (DCB) angioplasty is a promising treatment for ISR (8-11). DCB are semi-compliant and covered with an anti-proliferating drug; during angioplasty, they release this active agent into the vessel wall (12). However, it is not known whether DCB length is associated with clinical outcome. Longer DCBs are used in larger lesions as they release more anti-proliferative drug into the vessel wall; however, they cause more vessel injury. In this study, we conducted a hypothesis-generating pilot analysis of the Düsseldorf DCB registry. We aimed to associate DCB length and clinical outcome during hospital course and a 2-year follow-up.

Methods {#sec1-2}
=======

Study design, patient population, follow-up {#sec2-1}
-------------------------------------------

Data of 286 paclitaxel DCB (Pantera Lux, BIOTRONIK, SE & Co.KG, Berlin, Germany)-treated patients of the Düsseldorf DCB registry were analyzed in a retrospective manner. Of all the patients, 176 (61.8%) were treated using a 15-mm and 109 (38.2%) were treated using a 20-mm Pantera Lux DCB between April 2009 and June 2012. Quantitative coronary stenosis assessment (QCA) was not performed, and the lesion length was estimated regarding the pre-dilatation parameters by an interventionalist. DCB inflation was performed, and inflation duration and pressure were registered and compared between the groups.

Follow-up was conducted during ambulatory care at the Cardiology Department of the Heinrich-Heine-University Clinic Düsseldorf (Düsseldorf, Germany). The analysis was approved by the Ethics Committee of the Heinrich-Heine-University Düsseldorf (Düsseldorf, Germany).

Study endpoints {#sec2-2}
---------------

The incidences of TLR, MI, and all-cause death were investigated during hospital course and at 2-year follow-up appointment. Signs of ischemia, elevation of cardiac enzyme levels, and angiographically proven culprit lesion defined MI. Repeated revascularization of the DCB target lesion without meeting MI criteria was defined as TLR.

Statistical analysis {#sec2-3}
--------------------

Statistical analysis was performed using IBM SPSS^©^-Software (New York, USA) and GraphPad Prism statistical software (GraphPad Software Inc, San Diego). Calculation of relative risk (RR) with 95% confidence interval (CI) was done according to Altman (13). Hazard ratios (HRs) with 95% CI and log-rank test were used in MACE analysis. Normal distribution was tested using histograms, QQ-plots, and Kolmogorov-Smirnov test. Gaussian-distributed continuous variables were analyzed using t-test. Non-normally distributed variables were assessed using Mann-Whitney U test. Categorical variables were analyzed using Fisher's exact and Χ^2^ tests as applicable. All tests were two tailed, and p\<0.05 was considered significant. This was a hypothesis-generating explorative analysis; therefore, no power calculation was conducted.

Results {#sec1-3}
=======

Baseline characteristics {#sec2-4}
------------------------

Mean age of the study population was 73±10 years; 121 (68.4%) patients were male. Gender and body mass index (27±5 vs. 28±5; p=0.368) did not differ between the groups. Likewise, there were no significant differences between the groups regarding cardiovascular risk factors, medical history, clinical presentation, left ventricular function, or medication at discharge. Detailed baseline characteristics are illustrated in Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"} and [Supplemental 1](#T5){ref-type="table"}.

###### 

Patients characteristics

                                         15 mm          20 mm        *P*-value[\*](#t1f1){ref-type="table-fn"}
  -------------------------------------- -------------- ------------ -------------------------------------------
  Characteristics                                                    
  Age, years (mean ± SD)                 73±10          73±10        0.670
  Male gender, no. (%)                   121 (68.44%)   83 (76.1%)   0.121
  Height, cm (mean ± SD)                 174±9          171±9        0.622
  Weight, kg (mean ± SD)                 82±18          81±17        0.279
  Body mass index, kg/m^2^ (mean ± SD)   27±5           28±5         0.368
  Cardiovascular risk factors, no. (%)                               
  Hypertension                           177 (100%)     109 (100%)   \>0.999
  Hypercholesterolemia                   168 (95%)      105 (96%)    0.771
  Diabetes mellitus                      58 (33%)       44 (40%)     0.212
  Current smokers                        58 (33%)       28 (26%)     0.225
  Obesity (BMI \>30 kg/m^2^)             39 (22%)       26 (24%)     0.771
  Medical history, no. (%)                                           
  Prior myocardial infarction            74 (42%)       50 (46%)     0.536
  Prior CABG                             30 (17%)       21 (19%)     0.642
  Prior stroke                           10 (6%)        7 (6%)       0.801
  Chronic kidney disease                 52 (29%)       30 (28%)     0.788
  Dialysis                               5 (3%)         2 (2%)       0.707

*P*-value of Fischer's exact and Χ^2^ tests in categorical variables and t-test in continuous variables; BMI - body mass index; CABG - coronary artery bypass surgery

###### 

Clinical presentation and systolic left ventricular function

                                           15 mm      20 mm      *P*-value[\*](#t2f1){ref-type="table-fn"}
  ---------------------------------------- ---------- ---------- -------------------------------------------
  **Presentation, no. (%)**                                      
  ST-elevation myocardial infarction       8 (5%)     2 (2%)     0.331
  Non-ST-elevation myocardial infarction   27 (15%)   21 (19%)   0.423
  Instable angina pectoris                 62 (35%)   35 (32%)   0.699
  Stable coronary artery disease           70 (40%)   35 (32%)   0.208
  CCS-Stadium                                                    0.944
  CCS 0                                    60 (34%)   38 (35%)   
  CCS I                                    18 (10%)   11 (10%)   
  CCS II                                   35 (20%)   16 (15%)   
  CCS III                                  25 (14%)   12 (11%)   
  CCS IV                                   39 (22%)   32 (29%)   
  NYHA-Stadium                                                   0.123
  NYHA I                                   77 (44%)   50 (46%)   
  NYHA II                                  53 (30%)   38 (35%)   
  NYHA III                                 32 (18%)   19 (17%)   
  NYHA IV                                  15 (8%)    2 (2%)     
  **Left ventricular function, no (%)**                          
  Normal                                   95 (54%)   60 (55%)   0.902
  Mildly decreased                         37 (21%)   28 (26%)   0.377
  Moderately decreased                     25 (14%)   10 (9%)    0.260
  Severely decreased                       20 (11%)   11 (11%)   0.851

*P*-value of Fischer's exact and Χ^2^ tests; CAD - coronary artery disease; CCS - Canadian Cardiovascular Society; NYHA - New York Heart Association

###### 

Medication

                                    15 mm       20 mm       *P*-value[\*](#ts1f1){ref-type="table-fn"}
  --------------------------------- ----------- ----------- --------------------------------------------
  Medication -- no. (%)                                     
  Aspirin                           161 (91%)   104 (95%)   0.24
  P2Y12 inhibitor                   172 (97%)   108 (99%)   0.41
  Oral anticoagulation              41 (23%)    16 (15%)    0.09
  ACE- /AT-II-receptor- inhibitor   153 (86%)   95 (87%)    0.86
  Beta- blocker                     147 (83%)   97 (89%)    0.23
  Calcium- channel inhibitor        46 (26%)    28 (26%)    0.95
  Aldosterone antagonist            20 (11%)    12 (11%)    0.94
  Cardiac glycoside                 15 (8%)     5 (5%)      0.24
  Proton-pump inhibitor             59 (33%)    36 (33%)    0.96
  Statin                            147 (83%)   98 (90%)    0.12
  Oral antidiabetic                 35 (20%)    19 (17%)    0.64
  Insulin                           14 (8%)     12 (11%)    0.4
  Allopurinol                       32 (18%)    22 (20%)    0.76
  NSAID                             2 (1%)      1 (1%)      0.86
  Dipyrone                          3 (2%)      4 (4%)      0.43
  Morphine                          10 (6%)     3 (3%)      0.38

*P*-value of Fischer's exact test and Chi-squared test; ACE -- angiotensin-converting-enzyme; AT -- angiotensin; NSAID -- non steroidal anti inflammatory drug

DCB intervention {#sec2-5}
----------------

DCB procedure was successfully performed in 278 (97.5%) cases. Mean inflation duration was 50.2±12 s, and mean inflation pressure was 10.53±3.7 atm. There were no differences regarding inflation pressure and duration between the groups. Vessel dissection was seen in 21 (7.4%) patients. Overall, the left anterior descending artery was the predominant target vessel (42% vs. 34%, p=0.320). BMS-ISR was the most common cause for DCB intervention (46% vs. 51%, p=0.472). Bifurcation lesions were significantly more often treated using a 15-mm DCB (15% vs. 2%, p\<0.001). Vessel dissection incidence, inflation pressure, inflation duration, and vessel diameter was similar in both groups. An additional stent implantation during DCB procedure was seen in 48 (16.8%) cases, and it did not differ between the groups. Procedure-related data has been presented in [Table 3](#T4){ref-type="table"} and [Supplemental 1](#T5){ref-type="table"}. All types of lesions were included (including saphenous graft lesions, n=22). There were no re-conducted DCB interventions after initial DCB interventions in this cohort ([Supplemental 2](#T6){ref-type="table"}).

###### 

Drug-coated balloon procedure

                                   15 mm       20 mm       *P*-value[\*](#t3f1){ref-type="table-fn"}
  -------------------------------- ----------- ----------- -------------------------------------------
  **Balloon (mean±SD)**                                    
  Diameter (mm)                    3.04±0.6    3.06±0.7    0.783
  Inflation pressure (atm)         10.15±3.2   10.90±4.1   0.087
  Inflation duration (s)           49.83±12    50.56±12    0.621
  **Vessel dissection, no. (%)**   13 (7%)     7 (6%)      0.820
  **Combinations, no (%)**                                 
  DCB only                         145 (82%)   93 (85%)    0.508
  DCB+Bare metal stent             16 (9%)     8 (7%)      0.659
  DCB+Drug eluting stent           16 (9%)     8 (7%)      0.660
  **Procedural result, no. (%)**                           
  Angiographic success             173 (98%)   105 (96%)   0.481
  No success                       4 (2%)      4 (4%)      0.480

*P*-value of Fischer's exact and Χ^2^ tests in categorical variables and t-test in continuous variables; DCB - drug-coated balloon

###### 

Target vessel and drug-coated balloon indication

                             15 mm              20 mm            *P*-value[\*](#ts2f1){ref-type="table-fn"}
  -------------------------- ------------------ ---------------- --------------------------------------------
  Target vessel -- no. (%)                                       
  Left anterior descending   75 (42%)           38 (34%)         0.320
  Left circumflex            36 (20%)           28 (26%)         0.311
  Right coronary artery      49 (27%)           35 (32%)         0.425
  Venous bypass graft        15 (8%)            7 (6%)           0.649
  Ramus intermedius          2 (1%)             1 (1%)           0.863
  Indication -- no. (%)                                          
  BMS ISR                    82 (46%)           56 (51%)         0.472
  DES ISR                    43 (24%)           30 (27%)         0.570
  Bifurcation                **26** (**15**%)   **2** (**2**%)   **\<0.001**
  De-novo lesion             19 (11%)           16 (15%)         0.362
  Others                     7 (4%)             5 (5%)           0.774

*P*-value of Fischer's exact test and Chi-squared test; BMS -- bare metal stent; DES -- drug eluting stent

Study endpoints {#sec2-6}
---------------

During hospital course, the occurrence of MACE was similar between 15-mm and 20-mm DCB groups \[3 patients (1.7%) vs. 3 patients (2.8%), p=0.554)\]. Likewise, at 2-year follow-up, MACE did not significantly differ between the groups \[41 patients (23.2%) vs. 30 (27.5%), p=0.408; [Table 4](#T6){ref-type="table"}, [Fig. 1](#F1){ref-type="fig"}\]. During follow-up period, one patient died. MACE was predominantly caused by TLR (21.7% of 15-mm DCB-treated patients vs. 22% of 20-mm DCB-treated patients, p=0.925). MI occurred numerically more frequently in 20-mm DCB-treated patients (12.8% vs. 7.3%, p=0.294; [Table 4](#T6){ref-type="table"}).

###### 

Occurrence of MACE

                                    All          15 mm        20 mm        *P*-value
  --------------------------------- ------------ ------------ ------------ -----------
  **MACE during hospital course**   6 (2.1 %)    3 (1.7%)     3 (2.8%)     0.554
  Death                             1 (0.3%)     1 (0.6%)     0 (0.0%)     0.427
  Myocardial infarction             2 (0.7%)     1 (0.6%)     1 (0.9%)     0.931
  TLR                               3 (1.1%)     2 (1.1%)     1 (0.9%)     0.341
  **MACE at 2-year follow-up**      71 (24.8%)   41 (23.2%)   30 (27.5%)   0.408
  Death                             1 (0.3%)     0 (0.0%)     1 (0.9%)     0.203
  Myocardial infarction             25 (8.7%)    13 (7.3%)    14 (12.8%)   0.294
  TLR                               62 (21.7%)   38 (21.4%)   24 (22.0%)   0.925

\**P*-value of Χ^2^ test in categorical variables; MACE - major adverse cardiac events; TLR - target lesion revascularization

![Drug-coated balloon length and MACE. Drug-coated balloon length in coronary intervention was not associated with the incidence of major adverse cardiac events (MACE; death, myocardial infarction, and target lesion revascularization) during hospital stay (a) and at 2-year follow-up (b)](AJC-19-382-g001){#F1}

Discussion {#sec1-4}
==========

The major finding of this pilot analysis was that DCB length is not associated with MACE.

By now, it is well known that coronary stent length is a predictor for outcome for ISR (3-5). Enhanced stent length is associated with more vascular injury as well as increased platelet activation and higher risk of stent thrombosis (14). At the moment, either a DCB angioplasty or a percutaneous coronary intervention with everolimus-eluting stents (that gives best angiographic and clinical results) is recommended in ISR (8). DCB angioplasty is particularly very promising in ISR as no additional stent layer is needed. In a previous analysis, we demonstrated that Pantera Lux DCBs were superior to Sequent Please DCBs in prevention of adverse events (15). A tendency towards a higher incidence of MACE in patients treated with longer DCBs was observed. Therefore, we aimed to systematically investigate this issue in the present analysis. Contrary to our initial expectation, the present study suggests that DCB length does not impact the clinical outcome. Although patients undergoing treatment using 20-mm DCB might have had longer lesions, their outcome was not impaired. Hypothetically, a higher release of paclitaxel could counterbalance the more extensive stage of coronary artery disease represented by longer lesions.

However, this pilot study had several limitations. The number of patients in this pilot analysis was limited. It was a non-randomized, single-center analysis; however, it reflected a real-world population. Moreover, due to the retrospective design of this analysis, procedural data are limited; especially, QCA was not routinely conducted. Although QCA is a known standard procedure, there is also some evidence for an inter-core lab variability, especially concerning bifurcation stenosis (16). Moreover, it has been shown that evaluation of lesions using QCA is not superior to assessment by the interventional cardiologist (17). Therefore, lesion length is estimated regarding the pre-dilatation parameters by the interventionalist at our center. Furthermore, several patients presented with initial stent implantation which was conducted in external hospitals; thus, information about stent length was not available for every case. Consequently, standard ratios like stent to balloon length ratio and lesion to balloon length ratio are missing in this study. Additionally, no intravascular ultrasound or optical coherence tomography was performed. Therefore, we were unable to evaluate angiographic mismatch. Despite these important limitations regarding procedural details, the aim of this pilot study was to focus on the evaluation of DCB length as predictor of clinical outcome. We concluded that DCB length was not associated with clinical outcome.

The results of this study might lead to the hypothesis that a moderate oversizing of DCB does not affect long-term clinical outcome. However, despite the fact that there were no significant differences in clinical outcome, MACE were numerically higher in 20-mm DCB-treated patients. Additionally, 15-mm DCBs were more frequently used in bifurcation stenosis cases. Besides that, patients' characteristics, prior disease, clinical presentation, and procedural details did not significantly differ between the groups. However, even non-significant differences might have biased the results. The number of patients was too small to allow reasonable multivariate analyses. In this rapidly evolving field owing to advanced technology, the findings of our study have to be confirmed in large-scale, randomized clinical trials and meta-analyses.

Conclusion {#sec1-5}
==========

DCB length was not associated with clinical outcome. Rates of MACE did not differ between the 15-mm and 20-mm DCB-treated patients during hospital stay and 2-year follow-up. These findings have to be reconfirmed in clinical trials and meta-analyses.
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